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Abstract
Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of unknown aetiology affecting the
large bile ducts and characterized by periductal fibrosis and stricture formation, which ultimately result in
biliary cirrhosis and liver failure. Arteriosclerosis involves the accumulation of altered lipids and lipoproteins
in large arteries; this drives inflammation and fibrosis and ultimately leads to narrowing of the arteries and
hypoperfusion of dependent organs and tissues.
Knowledge of the causative factors is crucial to the understanding of disease mechanisms and the
development of specific treatment. Based on pathogenetic similarities between PSC and arteriosclerosis,
we hypothesize that PSC represents "arteriosclerosis of the bile duct" initiated by toxic biliary lipids. This
hypothesis is based on common molecular, cellular, and morphological features providing the conceptual
framework for a deeper understanding of their pathogenesis. This hypothesis should stimulate translational
research to facilitate the search for novel treatment strategies for both diseases.
Background
Arteriosclerosis, a disease of the large arteries, represents
the single most important contributor to total disease bur-
den in developed countries [1,2]. From a pathomorpho-
logical point of view, arteriosclerosis is characterized by
smooth muscle cell hyperplasia or hypertrophy and
matrix protein accumulation in the vessel intima and
media, with lipid deposition leading to thickening and
induration of the arterial wall and subsequently to arterial
stenosis. Over the past decade, attention has become
focused on the critical link between modified lipids and
lipid products and the initiation and perpetuation of
inflammation in arteriosclerosis [3,4].
PSC, a disease of the large bile ducts with a poor median
survival of 12 years, is characterised by chronic bile duct
inflammation leading to biliary fibrosis and finally cirrho-
sis. It is often complicated by cholangiocarcinoma (10–
15%) [5]. Due to the overall costs to society related to its
morbidity, mortality, and need for liver transplantation,
PSC in young adults and cholangiopathies in general are
increasingly recognized as very important liver diseases
[6]. The lack of effective medical treatments for PSC may
be deeply rooted in the lack of understanding of the dis-
ease mechanisms of PSC.
Based on similar pathogenetic features and mediators
found in both entities (summarized in Table 1 and dis-
played in Figure 1 and 2, we postulate that PSC shares
common disease mechanisms with arteriosclerosis vice
versa which may become therapeutic targets in the near
future in both diseases.
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Common Pathways in the Pathogenesis of Arteriosclerosis 
and Primary Sclerosing Cholangitis
Although Virchow first described arteriosclerosis as an
inflammatory disorder in 1885 it has taken a long time to
become recognised in modern medicine as an active
inflammatory disease rather than simply a problem of
lipid storage in the vessel wall. In the following we present
analogies and potential common pathogenetic mecha-
nisms in the pathobiology of arteriosclerosis and PSC
based on recent findings derived from animal models for
both diseases [7-10]. Even when it is taken into account
that the human body may have a limited repertoire of
reactions to noxious and/or infectious stimuli, the simi-
larities between PSC and arteriosclerosis in regard to their
pathobiology are stunning and deserve further explora-
tion.
Exposure to abnormal luminal lipid content: blood versus 
bile – toxic serum lipids versus cholephiles
All known critical molecular and cellular events underly-
ing the pathogenesis of arteriosclerosis are apparently
linked to alterations in lipid homeostasis [3]. As such, the
induction of endothelial vascular cell adhesion molecules
(Table 1), currently believed to represent the major initia-
tors in arteriosclerosis, is related to the accumulation of
oxidized LDL (oxLDL) and phospholipids on the
Table 1: Factors common to arteriosclerosis and sclerosing cholangitis
Arteriosclerosis Sclerosing Cholangitis
Co-factors
-Gender: Age below 60, men develop coronary heart disease twice as 
frequently as women
-Infectious agents: e.g. Chlamydia pneumoniae
-Systemic inflammation: elevated CRP levels, associated rheumatoid 
arthritis
Co-factors
-Gender: Males are affected twice as often as females
-Infectious agents: e.g. increased prevalence of chlamydial antibodies, 
pos. immunostaining for LPS in bile duct epithelial cells
-Systemic inflammation: elevated CRP levels, strongly associated with 
inflammatory bowel disease
Abnormal luminal content (blood composition)
-Lipoproteins
-Oxidized LDL
-Oxidized phospholipids
-Cholesterol
Abnormal bile composition
-Bile acids
-Cholesterol (supersaturated bile, oxidized?)
-Phospholipids(reduced, oxidized?, metabolites?)
Activated endothelial cells
-Adhesion molecules and receptors: VCAM-1, ICAM-1, PCAM-1, E-
selectin, P-selectin, CD39, CD40, CD44, P2Y, CXCRs, ADAMs, NTFs/
NTRKs
-Cyto- and chemokines: CXCL, MCP-1, TNF-α, IL-1β, IL-6, IL-8, 
fractalkine, osteopontin
-Growth factors: CTGF, PDGF-β, VEGF, EGF, ET-1, TGF-β
-Tight junction alterations: ZO-1, claudin-1, induction of NOS (iNOS)
Activated bile duct epithelial cells
-Adhesion molecules and receptors: VCAM-1, ICAM-1, E-selectin, 
CD39L1, CD40, CD44, P2Y, CXCRs, ADAMs, NTFs/NTRKs
-Cyto- and chemokines: CXCL, MCP-1, TNF-α, IL-1β, IL-6, IL-8, 
fractalkine, osteopontin
-Growth factors: CTGF, PDGF-β, VEGF, EGF, ET-1, TGF-β
-Tight junction alterations: ZO-1, claudin-1, induction of NOS (iNOS)
Inflammatory cells
-Monocytes/macrophage/foam cells: ROS, IL-6, IL-1, TNF-α, MMPs
-T cells: INF-γ, TNF-α, IL-1, IL10
Inflammatory cells
-Neutrophil granulocytes: ROS, IL-6, IL-1, TNF-α, MMPs
-T cells: INF-γ, TNF-α, IL-1, IL10
Smooth muscle cells
-MMPs: 1, 2, 3, 8, 9, 13,14
-ADAMTS: 1, 13
-TIMPs: 1, 2, 3
-Growth factors and chemokines: HGF, ET-1, TGF-β, ACE2I, 
RANTES
-Matrix deposition: collagen, elastic fibres, glycoproteins, 
proteoglycanes
Periductal myofibroblasts
-MMPs: 1, 8, 13
-ADAMTS: 13
-TIMPs: 1, 2, 3, 4
-Growth factors and chemokines: HGF, ET-1, TGF-β, MCP-1, MIP-2, 
ACE2, RANTES
-Matrix deposition: collagen, elastic fibres, glycoproteins, 
proteoglycanes
ACE2, angiotensin converting enzyme II; ADAM, a disintegrin and metalloproteinase domain; ADAMTS, a disintegrin-like metallopeptidase with 
thrombospondin type 1 motif; CD40-antigen, TNF receptor superfamily; CD44, CD44 antigen; CLDN1; claudin 1; CTGF, connective tissue 
growth factor; CXCLs chemokines, C-X-C motif ligand; CXCRs, chemokine C-X-C motif receptors; CD39/NTPDase-1, ectonucleoside 
triphosphate diphosphohydrolase 1;CD39L1/NTPDase-2, ectonucleoside triphosphate diphosphohydrolase 2; EGF, epidermal growth 
factor;ET-1, endothelin 1; HGF; hepatocyte growth factor; ICAM-1 intercellular adhesion molecule 1; INF-γ, interferon gamma; IL1-β, 
interleukin 1 beta; IL-6; interleukin 6; IL-8; interleukin 8; Mcp-1; monocyte chemoattractant protein-1; MIP-2, chemokine (C-X-C motif) ligand 2; 
MMPs, matrix metallopeptidases; NTFs neurotrophins; NTRKs, neurotrophic tyrosine kinase receptor;PCAM-1, polymorph nuclear cell 
adhesion molecule; PDGF-β; platelet-derived growth factor beta polypeptide); P2Y purinergic receptor G-protein coupled; RANTES, chemokine 
ligand 5; TGF-β, transforming growth factor beta 1; TIMP1, tissue metallopeptidase inhibitor 1; TJP1, tight junction protein 1; ZO-1, zona 
occludens 1; TNF-α, tumor necrosis factor-alpha; VCAM-1, vascular cell adhesion molecule 1; VEGF, vascular endothelial growth factor.Lipids in Health and Disease 2007, 6:3 http://www.lipidworld.com/content/6/1/3
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Model of the Development of Arteriosclerosis Figure 1
Model of the Development of Arteriosclerosis. (1) Low-density lipoprotein (LDL) moves into the subendothelial space 
and becomes oxidized. (2) Inflammatory cells are recruited into the vessel wall via induced endothelial adhesion molecules 
(VCAM, ICAM) and (3) take up oxidized LDL and become foam cells. (4) Activation of macrophages leads to the release of 
inflammatory cytokines, chemokines, inflammatory molecules and reactive oxygen species leading to (5) the perpetuation of 
inflammation and tissue damage. (6) Antigens presented by macrophages and dendritic cells trigger the activation of cytotoxic 
T-cells, which produce Th-1 cytokines and heat-shock proteins as well as TGF-β, which activates smooth-muscle cells (7).
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5 Perpetuation of inflammation
and tissue damage
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Model of the Development of Primary Sclerosing Cholangitis Figure 2
Model of the Development of Primary Sclerosing Cholangitis. (1) Toxic bile (e.g. toxic bile acids, oxidized/modified 
cholesterol and phospholipids) causes (2) the induction of a reactive phenotype of cholangiocytes characterized by de novo 
expression or overexpression of adhesion molecules, inflammatory and profibrogenetic cytokines, and receptors (e.g. TNF-α, 
TGF-β, toll-like receptors, VCAM, CD44). (3) Proinflammatory cytokines induce leakiness of the bile duct epithelium leading 
to regurgitation of bile into the portal space, leading to (4) transmigration of (5) neutrophils and (6) lymphocytes and their acti-
vation. Bile duct epithelial cell-derived growth factors and cytokines (e.g. TGF-β, PDGF) and reactive molecules released from 
neutrophils (7) (e.g. ROS, 4-HNE) stimulate extracellular matrix production, accumulation, and proliferation of (8) periductal 
myofibroblasts, leading to periductal fibrosis and in consequence to vascular deprivation of the bile duct system itself, causing 
(9) death of bile duct epithelial cells. Bile duct epithelial cell-derived growth factors (e.g. EGF, HGF, PDGF, BDNF) may also 
activate and recruit bone marrow derived progenitor cells into the portal field probably engaged in ductal reaction and prolif-
eration of periductal MFBs.
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endothelial surface (Figure 1) [3]. As such, oxidized lipo-
protein particles (e.g. oxidized phospholipids and short-
chain aldehydes arising from lipoprotein oxidation) can
induce endothelial VCAM-1 expression via TNF-α- or IL1-
β-induced nuclear factor-κB activation [4].
Since the liver is the major organ responsible for the pro-
duction and degradation of apoB-100-containing lipo-
proteins, it is most likely that these molecules may also be
engaged in the pathogeneses of liver diseases. Moreover,
the fact that bile secretion is the most effective means of
cholesterol elimination from the human body leads to the
suggestion that altered biliary lipid secretion and/or
abnormal lipid oxidation leading to oxidative stress may
also be critically involved in the initiation and/or perpet-
uation of PSC. In parallel to arteriosclerosis, enhanced
cholangiocellular VCAM-1 expression was recently dem-
onstrated in multidrug resistance gene (Mdr2/Abcb4)
knockout mice (Mdr2-/-), a well characterized mouse
model that closely mirrors the macroscopic and micro-
scopic pathology of PSC [8,11]. Potentially toxic bile acids
synthesized from cholesterol may represent first-line can-
didates for the induction of cholangitis in Mdr2-/- mice
[12]. Bile acids are normally packed into mixed micelles
together with phospholipids and cholesterol to protect
cholangiocytes from potentially toxic bile acids, which
may otherwise cause necrosis or apoptosis of cholangi-
ocytes [6]. Absence of phospholipids as a consequence of
Mdr2 defects not only results in unopposed bile acid tox-
icity but also in cholesterol supersaturated bile, which
could facilitate oxidation. The critical role of biliary lipo-
toxicity in the sense of deranged and consequently toxic
bile composition in the development of cholangitis was
also underlined by the enhanced cholestatic phenotype in
bile acid-fed Mdr2-/- mice [13]. Despite the apparent dis-
crepancy between decreased biliary cholesterol concentra-
tion in Mdr2-/- mice and increased serum cholesterol levels
in arteriosclerosis, the common denominator may be
abnormal cholesterol oxidation in both conditions. Alter-
natively, abnormal metabolic products of phosphatidyl-
cholines (e.g. lysoPC) could also be excreted into bile in
Mdr2-/- mice or reach the cholangiocytes also from the per-
biliary plexus or lymph vessels instead from the luminal
side. Moreover, bile acids may be able to induce a reactive
phenotype of cholangiocytes characterized by the produc-
tion of several proinflammatory and profibrogenic
cytokines and chemokines as well as their corresponding
receptors (summarized in Table 1 and shown in Figure 2)
[6]. Conversely, some bile acids, their receptors, and syn-
thetic agonists were recently shown to influence the
degree of arteriosclerosis in several animal models [14-
18]. This fits well with the rapidly progressing insights
into the transcriptional regulation by nuclear receptors
(e.g. FXR, LXR) of bile acid synthesis/transport on the one
hand and lipid metabolism/transport on the other
[17,19,20]. Finally, toxic bile acids can activate endothe-
lial cells [21]. Taken together, exposure to abnormal lumi-
nal lipid content and composition, ultimately resulting in
lipid oxidation, may be critically involved in both condi-
tions.
Activated endothelial cells versus reactive cholangiocytes – 
mechanisms of chemoattraction in arteriosclerosis and 
PSC
Endothelial and bile duct epithelial cells may not only be
the victims/targets but also the culprits/effectors that
actively participate in inflammatory processes in arterio-
sclerosis and PSC, respectively. The endothelium repre-
sents the first-line contact, where the accumulation of
oxLDL induces the expression of adhesion molecules
(e.g., VCAM-1) and proinflammatory cytokines/chemok-
ines (e.g., MCP-1, see also Table 1) critically involved in
the initiation and perpetuation of arteriosclerosis, making
them potential therapeutic targets [4]. Most interestingly,
the cytokine/chemokine/receptor armamentarium of
reactive endothelial cells and reactive cholangiocytes
appears to be largely comparable, as summarized in Table
1[6].
Altered endothelial versus altered epithelium barrier 
function – mechanisms of leukocyte penetration and 
activation
Endothelial binding and penetration of monocytes and T
lymphocytes in nascent atheromas by adhesion molecules
is pivotal in the development of arteriosclerosis [4]. More-
over, induction of endothelial-derived adhesion mole-
cules reduces barrier function via alterations of the
delicately regulated tight junction system, allowing oxi-
dized lipids and marginalized/attached inflammatory
cells to migrate into subendothelial regions of the vessel
[22]. The MCP-1/CCR2 interaction together with the
action of M-CSF represents a critical step for migrated
monocytes to differentiate into activated macrophages/
foam cells, which themselves are able to produce numer-
ous cytokines, reactive oxygen species (ROS), and growth
factors (Table 1). Penetrating T lymphocytes further per-
petuate this inflammatory response in a complex orches-
trated interplay of cytokines and tissue factors (Table 1,
Figure 1).
In analogy to arteriosclerosis, hydrophobic bile acids can
induce MCP-1 and TNF-α expression to increase tight
junction permeability of cholangiocytes in vitro [23,24].
In line with these findings, increased tight junction per-
meability was also demonstrated in Mdr2-/-  mice and
human cholangiopathies, a mechanism which could per-
mit regurgitation of bile (rich in bile acids, phospholipids,
cholesterol, lipoprotein X, CD66a) from the bile duct
lumen into the portal tract (Figure 2) [8,25]. Leaking of
potentially chemotactic/reactive cholephiles togetherLipids in Health and Disease 2007, 6:3 http://www.lipidworld.com/content/6/1/3
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with enhanced expression and secretion of adhesion mol-
ecules may then induce the migration of neutrophils and
T lymphocytes from the peribiliary plexus out into the
subepithelial space and into the bile duct epithelium,
leading to cholangitis (Figure 2). Despite the fact that
cytotoxic T cells were shown to induce cholangiocyte
apoptosis in humans [26], their role in PSC is still a matter
of debate since these cells are virtually absent in precir-
rhotic PSC stages. The hypothesis becomes questionable
that cholangiocytes are the primary target of the immune
system in PSC. The role of portal and/or penetrated neu-
trophils (probably leading to ROS formation and destruc-
tion of the basement membrane) in PSC also deserves
more detailed studies because these cells may be critically
involved in the activation of periductal myofibroblasts by
aldehydic end-products of lipid peroxidation.
Endothelial cell – smooth muscle cell interactions in 
arteriosclerosis versus bile duct epithelial cell – periductal 
myofibroblast interactions in PSC
Differentiated monocytes/macrophages and T cells that
find their way out through the leaky endothelial barrier
exert their pro-atherogenic effects by the secretion of
cytokines and growth factors driving smooth muscle cell
(SMC) migration and proliferation as well as extracellular
matrix (ECM) deposition (Table 1). The development of
fibrous plaques results from proliferating SMCs, choles-
terol ester and ECM components. This complex interplay
is mediated by extensive crosstalk between T-cells and
macrophages (CD40/CD40L interactions). Increased
homocystein and angiotensin II levels in the vessel wall
were also demonstrated to be important mediators of
SMC proliferation as well as their activation. In addition,
molecules such as osteopontin, CD44 and TGF-β were
demonstrated to be critically involved in SMC activation.
Reduction of arteriosclerosis in corresponding athero-
genic diet-fed knock-out mice [27-29] further underlines
the importance of these factors for the development of
arteriosclerosis.
A number of these central mediators of arteriosclerosis
were also demonstrated to originate from activated
cholangiocytes in cholangiopathies [30-32] (Table 1 and
Figure 2). Cholangiopathies are frequently accompanied
by ductular proliferation/reaction, which is a potential
stimulus for biliary fibrosis. The question whether ductu-
lar proliferates induce/stimulate proliferation and activa-
tion of periductal myofibroblasts and how this might
happen (e.g., via stimulation with cytokines such as TGF-
β or PDGF, brain-derived peptides such as NGF and
BDNF, epithelial-mesenchymal transformation) is critical
and still to be resolved.
Remodelling of the extracellular matrix as self-
perpetuating events in arteriosclerosis and PSC
Little is known about the potential importance of the
extracellular matrix composition in the pathogenesis of
both entities and how modifications (e.g. binding of
oxLDL/phospholipids to proteoglycans, cleavage and sig-
nalling through proteinases, collagenases, gelatinases,
resulting advanced glycosylated endproducts or trans-
glutamination of collagen fibres) could influence the per-
petuation of both diseases. In arteriosclerosis, diminished
stability of the matrix scaffold is driven by MMPs, colla-
genases, and the recently identified ADAMTSs (a disin-
tegrin-like metalloprotease with thrombospondin type-1
motifs) [33]. These enzymes could either play a role in the
resolution of vessel stenoses or also destabilize plaques
[34,35]. In parallel, these enzymes could also be engaged
in the chronic persistent wound-healing process in PSC. It
is attractive to speculate that chronic activation of MMPs
could further increase duct permeability. In addition, per-
sistent activation of ADAMTSs could further increase the
inflammatory response through their thrombospondin-1
motive (TSP-1) on TGF-β [36,37] or in the sense of a self-
perpetuating process by generating chemotactic/immuno-
genic ECM products.
Limitations and caveats using Mdr2-/- mice as a model 
system for PSC
The exact role of MDR3 variants (the human orthologue
of rodent Mdr2) in the pathogenesis of PSC is still open to
question. Two studies (with a total number of 80 PSC
patients) found no differences in the number of genetic
MDR3  variants between healthy individuals and PSC
patients [38,39]. The findings of these two genetic studies
are consistent with a normal biliary bile acid/PC ratio
(indicative of normal MDR3 function) previously
reported in 45 PSC patients [40]. However, the number of
PSC patients tested so far is still to small to definitely
answer the question whether MDR3 defects may play a
pathogenetic role and reductions in PC excretion may be
transient and independent of genetic factors. Moreover,
since PSC may represent a complex/polygenetic disease, a
major role of MDR3  mutations in "unselected" PSC
patients would be surprising. Rather, MDR3 genetic varia-
tions could play a role in selected PSC subgroups (e.g.,
small duct PSC, young women suffering from PSC, PSC
patients with gallstones). Such "unusual" PSC patients
could have been missed in previous studies despite the
fact that cholelithiasis can be part of its clinical spectrum
[41]. Although the role of MDR3 variants in the pathogen-
esis of PSC is still controversial, Mdr2 knockout mice may
still represent a worthwhile cholangiopathy model. The
Mdr2 knockout mouse model is the first and so far only
non-surgical animal model clearly showing the macro-
scopic (bile duct strictures and dilatations of the large bile
ducts) and microscopic features (onion skin-type likeLipids in Health and Disease 2007, 6:3 http://www.lipidworld.com/content/6/1/3
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pericholangitis and periductal fibrosis) of sclerosing
cholangitis in humans [8,42]. An additional advantage of
this model system is the high reproducibility and low var-
iance in the cholestatic phenotype of these animals mak-
ing them also an ideal model for therapeutic
interventional studies [43]. Irrespective of the underlying
cause of sclerosing cholangitis, the Mdr2-/- model is an
appropriate animal model for sclerosing cholangitis since
it reliably reproduces the final common pathways of bile
duct injury and (peri)biliary fibrosis. However, Mdr2-/-
mice do not show some of the (pheno)typical features
observed in human PSC such as the association with
cholangiocarcinoma and inflammatory bowel disease.
finally, the Mdr2-/- model may also have general validity as
model for cholangiopathies resulting from bile toxicity
with a deranged biliary phospholipid/bile salt secretion.
Differences between PSC and artieriosclerosis
Despite the stunning similarities between PSC and arteri-
osclerosis in regard to their pathobiology as outlined
above, there are also obvious differences between both
entities such as the age of onset, different risk factors, and
different co-factors (outlined in Table 1) which deserve
attention. The exact definition and discrimination of sim-
ilarities and differences between PSC and artiosclerosis
should further help to understand the pathogenesis of
both diseases.
How to test the hypotheses
(i) The toxic bile hypothesis could be tested by studying
bile composition with particular emphasis on biliary lip-
ids (e.g. oxidized/modified cholesterol and phospholip-
ids) and other candidate molecules (e.g. CD66a, E-
selectin, cyto-, and chemokines), either in bile sampled by
endoscopic techniques or assessed via non-invasive
modalities such as advanced MR technologies (MR spec-
troscopy).
(ii) In addition, detailed immunohistochemical studies in
PSC livers (either explanted organs or liver biopsy mate-
rial) using antibodies against adhesion molecules recently
identified on cholangiocytes and other well defined medi-
ator molecules in arteriosclerosis such as the receptor for
advanced glycosilated end products (RAGE) and oxidized
lipids/phospholipids should answer the question of
whether these molecules are indeed engaged in the patho-
genesis in PSC.
(iii) Ulcerated bile ducts are frequently observed in
explanted PSC livers and remind us, at least in some mor-
phological aspects, of plaque rupture in arteriosclerosis.
The frequency and importance of duct ulcerations in PSC
might be underestimated due to sampling errors inherent
to the technique of liver biopsy. Serial sections of
explanted PSC livers should help to answer the question
of whether concentric bile duct stenoses are the result of a
perpetuated wound-healing process of ulcerated/ruptured
bile ducts.
(iv) Basic research in PSC should determine the potential
role of new inflammatory mediators (e.g. adipokines)
known to be critically engaged in the pathogenesis of the
metabolic syndrome and consequently arteriosclerosis.
Conclusion
We postulate a pathogenetic link between PSC and arteri-
osclerosis. Our model provides a structured and unifying
pathogenetic model, based on biological, clinical, and
experimental evidence and a network of molecular simi-
larities between both entities. Scientific exchange between
researchers/scientists working either in the field of arteri-
osclerosis or cholangiopathies and cholestatic liver dis-
eases in general should be fruitful and stimulating.
Research on PSC may greatly benefit from translating
pathogenetic concepts from advanced work in arterioscle-
rosis to the study of cholestasis. However, this could also
work the other way around since it is becoming increas-
ingly apparent that arteriosclerosis may represent a kind
of "liver disease of the heart" [44].
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